Primary plasma cell leukemia and autologous stem cell transplantation
- 1 May 2010
- journal article
- research article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 95 (5), 804-809
- https://doi.org/10.3324/haematol.2009.013334
Abstract
Background Primary plasma cell leukemia is a rare disorder accounting for less than 5% of malignant plasma cell diseases. It has a poor prognosis compared to multiple myeloma, with a median survival of 8-12 months. The results of conventional therapy are disappointing though autologous stem cell transplantation may improve survival. Design and Methods A retrospective analysis was undertaken of the European Group for Blood and Marrow Transplantation experience of 272 patients with plasma cell leukemia and 20844 with multiple myeloma undergoing first autologous transplantation between 1980 and 2006. All patients were reported to the European Group for Blood and Marrow Transplantation registry using MED-A (limited data) or MED-B (extensive data) forms. All patients were included regardless of availability of complete data. Results There was no difference in type of graft or use of total body irradiation between patients with plasma cell leukemia and multiple myeloma, but the group with plasma cell leukemia was transplanted earlier after diagnosis (6.0 versus 7.7 months, P=0.000). Patients with plasma cell leukemia were more likely to enter complete remission after transplantation but their overall survival (25.7 months, 95% confidence interval 19.5-31.9 months) was inferior to that of patients with multiple myeloma (62.3 months, 95% confidence interval 60.4-64.3 months) (P=0.000), due to the short duration of their post-transplant response and increased non-relapse-related mortality. Conclusions This largest study ever reported on plasma cell leukemia suggests that autologous transplantation can improve outcome, although results are markedly inferior to those achieved in patients with multiple myeloma, highlighting the need for novel approaches to this aggressive disorder.Keywords
This publication has 28 references indexed in Scilit:
- Thalidomide does not modify the prognosis of plasma cell leukemia patients: Experience of a single centerLeukemia & Lymphoma, 2007
- Bortezomib is effective in primary plasma cell leukemiaLeukemia & Lymphoma, 2006
- Tumor Lysis Syndrome After Bortezomib Therapy for Plasma Cell LeukemiaPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2005
- Long-term survival in primary plasma cell leukemia after therapy with VAD, autologous blood stem cell transplantation and interferon-alpha.Acta Haematologica, 1999
- Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics.1999
- Total therapy with tandem transplants for newly diagnosed multiple myeloma.1999
- The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myelomaLeukemia, 1998
- Long-lasting complete remission in plasma cell leukemia after aggressive chemotherapy and CD34-selected autologous peripheral blood progenitor cell transplant: molecular follow-up of minimal residual diseaseBone Marrow Transplantation, 1998
- A randomized trial of maintenance interferon following high‐dose chemotherapy in multiple myeloma: long‐term follow‐up resultsBritish Journal of Haematology, 1998
- Consolidation therapy with autologous stem cell transplantation in plasma cell leukemia after VAD, high-dose cyclophosphamide and EDAP courses: a report of three cases and a review of the literatureBone Marrow Transplantation, 1997